Task force 3: Disclosure of relationships with commercial interests: policy for educational activities and publications.

tween industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170:477– 80. 22. Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. New Repub 2002; 227:27– 41. 23. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003;290:495–501. 24. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290: 516–23. 25. Hrachovec JB, Mora M. Reporting of 6-month vs. 12-month data in a clinical trial of celecoxib. JAMA 2001;286:2398–400. 26. McKillop T. The statin wars. Lancet 2003;362:1498. 27. Nathan DG, Weatherall DJ. Academia and industry: lessons from the unfortunate events in Toronto. Lancet 1999;353:771–2. 28. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Available at: www.icmje.org/ index.html#conflicts. 29. P.L. 96-517; 94 Stat. 3015 The Bayh-Dole Act. 12-12-1980. 30. Stolberg SG. The biotech death of Jesse Gelsinger. NY Times Magazine 1999;136–50. 31. Califf RM, Morse MA, Wittes J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24:256 –71.